- Home
- CUB vs THRD Comparison
CUB vs THRD Comparison
Compare CUB & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- THRD
- Stock Information
- Founded
- CUB 2024
- THRD 2019
- Country
- CUB United States
- THRD United States
- Employees
- CUB N/A
- THRD N/A
- Industry
- CUB
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- THRD Health Care
- Exchange
- CUB NYSE
- THRD Nasdaq
- Market Cap
- CUB 310.3M
- THRD 335.2M
- IPO Year
- CUB 2024
- THRD 2022
- Fundamental
- Price
- CUB $10.11
- THRD $6.00
- Analyst Decision
- CUB
- THRD Strong Buy
- Analyst Count
- CUB 0
- THRD 3
- Target Price
- CUB N/A
- THRD $20.33
- AVG Volume (30 Days)
- CUB 33.7K
- THRD 248.2K
- Earning Date
- CUB 01-01-0001
- THRD 11-07-2024
- Dividend Yield
- CUB N/A
- THRD N/A
- EPS Growth
- CUB N/A
- THRD N/A
- EPS
- CUB N/A
- THRD N/A
- Revenue
- CUB N/A
- THRD N/A
- Revenue This Year
- CUB N/A
- THRD N/A
- Revenue Next Year
- CUB N/A
- THRD N/A
- P/E Ratio
- CUB N/A
- THRD N/A
- Revenue Growth
- CUB N/A
- THRD N/A
- 52 Week Low
- CUB $9.96
- THRD $5.60
- 52 Week High
- CUB $10.55
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- THRD 23.75
- Support Level
- CUB N/A
- THRD $5.60
- Resistance Level
- CUB N/A
- THRD $11.78
- Average True Range (ATR)
- CUB 0.00
- THRD 0.89
- MACD
- CUB 0.00
- THRD -0.43
- Stochastic Oscillator
- CUB 0.00
- THRD 6.50
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.